Literature DB >> 14973080

Pheophorbide a is a specific probe for ABCG2 function and inhibition.

Robert W Robey1, Kenneth Steadman, Orsolya Polgar, Kuniaki Morisaki, Margaret Blayney, Prakash Mistry, Susan E Bates.   

Abstract

Pheophorbide a (PhA), a chlorophyll catabolite, was shown to be an ABCG2 substrate based on Abcg2(-/-) knockout mouse studies (J. W. Jonker et al., Proc. Natl. Acad. Sci. USA, 99: 15649-15654, 2002). We developed a functional assay for ABCG2 using PhA and the ABCG2 inhibitor fumitremorgin C. In selected cell lines expressing high levels of P-glycoprotein, multidrug resistance-associated protein 1, or ABCG2, PhA transport was observed only in cells expressing ABCG2. Fumitremorgin C-inhibitable PhA transport was found to correlate with cell surface ABCG2 expression as measured by the anti-ABCG2 antibody 5D3. We found that 100 micro M of the cyclin-dependent kinase inhibitor UCN-01 or 1 micro M of the P-glycoprotein inhibitor tariquidar inhibited ABCG2-mediated PhA transport. In 4-day cytotoxicity assays, ABCG2-mediated resistance to SN-38 and topotecan was abrogated in ABCG2-transfected HEK-293 cells treated with 1 micro M tariquidar, and ABCG2-transfected cells were 6-7-fold resistant to UCN-01. PhA is an ABCG2-specific substrate with potential value in measuring ABCG2 function and expression in clinical samples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973080     DOI: 10.1158/0008-5472.can-03-3298

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  100 in total

Review 1.  The controversial role of ABC transporters in clinical oncology.

Authors:  Akina Tamaki; Caterina Ierano; Gergely Szakacs; Robert W Robey; Susan E Bates
Journal:  Essays Biochem       Date:  2011-09-07       Impact factor: 8.000

2.  The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Authors:  Rupashree Sen; Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Hong-Bin Fang; Ling Cai; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

3.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Authors:  Pavitra Kannan; Sanjay Telu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  ACS Chem Neurosci       Date:  2010-10-21       Impact factor: 4.418

Review 4.  Transport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos.

Authors:  Tufan Gökirmak; Lauren E Shipp; Joseph P Campanale; Sascha C T Nicklisch; Amro Hamdoun
Journal:  Mol Reprod Dev       Date:  2014-08-22       Impact factor: 2.609

Review 5.  ABC transporters: unvalidated therapeutic targets in cancer and the CNS.

Authors:  Robert W Robey; Paul R Massey; Laleh Amiri-Kordestani; Susan E Bates
Journal:  Anticancer Agents Med Chem       Date:  2010-10-01       Impact factor: 2.505

6.  The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.

Authors:  Sung-Han Hsiao; Megumi Murakami; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2018-07-18       Impact factor: 8.679

7.  Design, synthesis, and biological evaluation of (S)-valine thiazole-derived cyclic and noncyclic peptidomimetic oligomers as modulators of human P-glycoprotein (ABCB1).

Authors:  Satyakam Singh; Nagarajan Rajendra Prasad; Khyati Kapoor; Eduardo E Chufan; Bhargav A Patel; Suresh V Ambudkar; Tanaji T Talele
Journal:  Chembiochem       Date:  2013-11-29       Impact factor: 3.164

8.  ABCG2 requires a single aromatic amino acid to "clamp" substrates and inhibitors into the binding pocket.

Authors:  Tomoka Gose; Talha Shafi; Yu Fukuda; Sourav Das; Yao Wang; Alice Allcock; Ailsa Gavan McHarg; John Lynch; Taosheng Chen; Ikumi Tamai; Anang Shelat; Robert C Ford; John D Schuetz
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

9.  Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

Authors:  Zhiyong Liao; Robert W Robey; Josée Guirouilh-Barbat; Kenneth K W To; Orsolya Polgar; Susan E Bates; Yves Pommier
Journal:  Mol Pharmacol       Date:  2007-11-05       Impact factor: 4.436

10.  The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.

Authors:  Zhi Shi; Smitaben Parmar; Xing-Xiang Peng; Tong Shen; Robert W Robey; Susan E Bates; Li-Wu Fu; Yining Shao; Yang-Min Chen; Feiyang Zang; Zhe-Sheng Chen
Journal:  Oncol Rep       Date:  2009-02       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.